Login to Your Account

In The Clinic NEWS

With its lead cancer drug unpartnered and a new CEO yet to be chosen, Synta Pharmaceuticals Corp. is advancing the phase II/III AML LI-1 trial to test the chemosensitizing mettle of the heat-shock protein 90 inhibitor ganetespib.

LONDON – Biosceptre Ltd. announced positive results from a U.S. phase I study of its lead antibody, BIL-010t, providing proof of concept for what the company said is a highly specific target found in at least 20 different cancers, and paving the way for a £20 million (US$34.2 million) funding round to take two products through to phase IIb development.
Amgen Inc.'s pipeline news of late has been dominated by the flood of data from its promising PCSK9-inhibiting cholesterol drug evolocumab, but the Thousand Oaks, Calif.-based firm reported more quietly late Thursday good news for its blockbuster secondary hyperparathyroidism (SHPT) franchise as AMG 416 hit all primary and secondary endpoints in its first phase III trial.
More In The Clinic Headlines

Cast Your Vote

Has biotech’s bubble burst?: